Heart-Disease Research Focuses on Drug for African-Americans; Shands Jacksonville Was Part of a Clinical Trial of BiDil, Which Is Being Marketed for One Race

By Black, Cherie | The Florida Times Union, August 13, 2005 | Go to article overview

Heart-Disease Research Focuses on Drug for African-Americans; Shands Jacksonville Was Part of a Clinical Trial of BiDil, Which Is Being Marketed for One Race


Black, Cherie, The Florida Times Union


Byline: CHERIE BLACK

After Jacksonville resident Johnnie Cherry suffered three heart attacks, his physician put him on a low-salt diet and inserted a pacemaker into his chest. The 49-year-old widower also was enrolled in a clinical trial in 2001 to determine whether a heart medicine targeted specifically for African-Americans actually worked.

The U.S. Food and Drug Administration recently approved the drug, called BiDil, marking one of the only times a drug has been marketed exclusively for one race.

BiDil is a combination of two generic drugs used to treat chest pain and high blood pressure.

The drug enhances the benefits of nitric oxide in heart patients. Nitric oxide is a substance produced by cells that protects the heart and arteries from damage. Research has shown African-Americans who suffer heart failure are more likely to have lower levels of nitric oxide. That is why BiDil worked more effectively in a study involving 1,050 African-American heart disease patients than it did for the general population. In that study, BiDil reduced mortality in African-Americans by 43 percent.

Those results led researchers to conduct a clinical trial aimed specifically at African-Americans.

The results of the three-year study, which was conducted at 170 sites across the country including Shands Jacksonville, showed the patients who took the new drug along with other heart treatments had a higher survival rate.

The trial was expected to be completed early this year, but the results were so impressive it was continued until July.

"African-Americans between the ages of 45 and 64 are 2.5 times more likely to die prematurely from heart failure than their non-black counterparts," said Anne Taylor, the trial's lead investigator from the University of Minnesota Medical School.

They also die earlier, she said.

"FDA approval of BiDil represents an important leap forward in addressing this health disparity," she said.

In Jacksonville the drug will be available to patients within the next couple of months, said Alan Miller, a University of Florida cardiologist and professor of medicine who led the clinical trial at Shands. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Heart-Disease Research Focuses on Drug for African-Americans; Shands Jacksonville Was Part of a Clinical Trial of BiDil, Which Is Being Marketed for One Race
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.